Home / Healthcare / Osteoarthritis Treatment Market by Drug type (Analgesics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Hyaluronic Acid, Pipeline Analysis), by Anatomy (knee, hip, ankle, shoulder & hand), by Channel of Distribution (Hospitals, Retail & Online), by Mode of Purchase (Prescription & OTC), by Route of Administration (Parenteral, Topical &Oral) - Growth, Share, Opportunities & Competitive Analysis, 2021 - 2029

Osteoarthritis Treatment Market by Drug type (Analgesics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Hyaluronic Acid, Pipeline Analysis), by Anatomy (knee, hip, ankle, shoulder & hand), by Channel of Distribution (Hospitals, Retail & Online), by Mode of Purchase (Prescription & OTC), by Route of Administration (Parenteral, Topical &Oral) - Growth, Share, Opportunities & Competitive Analysis, 2021 - 2029


Published: Jun 2021

The global osteoarthritis treatment market is projected to grow at a CAGR of 9.0%. Improving healthcare sector, treatment types, safety& emerging technologies are driving the market growth. Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It occurs when the protective cartilage that cushions the ends of your bones wears down over time.  However osteoarthritis can damage any joint, the disorder most commonly affects joints in your hands, knees, hips & spine. There is an increase in risk of osteoarthritis as age increases. Various diseases arising due to age factor are accounted on large scale. According to OAFI Osteoarthritis Foundation International Osteoarthritis accounts for more than 500 million people affected worldwide. The prevention of such diseases is important to ensure a healthy life span. Technologies have emerged in developed countries as North America & are spending about more than $ 500 million for the research of arthritis. In a society where the population’s life expectancy is on the rise, conditions such as these are to be considered as a priority as this severely impacts the quality of life.

Non-steroidal Anti-inflammatory Drugs (NSAIDs) application on large scale

Non-steroidal Anti-inflammatory Drugs (NSAIDs) treatment has played a vital role in treatment of this disease. Prostaglandins are a family of chemicals that are produced by the cells of the body and have several important functions. Prostaglandins are produced within the body's cells by the enzyme cyclooxygenase (COX), there are two COX enzymes, COX-1 and COX-2.Examples of the most common NSAIDs include: aspirin salsalate (Amigesic), diflunisal (Dolobid), ibuprofen (Motrin), ketoprofen (Orudis). However there are some side effects caused by this treatment various research & efforts are being made to overcome them. The adverse effect of this treatment on other parts is treated along with it.  Advances in technology are making enormous efforts to treat such diseases; similar efforts are also taken by non-profit organizations as OAFI Osteoarthritis Foundation International& WHO world health organization. Pharmaceutical company such as Lupin Limited has received approval from by FDA for Meloxicam capsules in 2020.

Above 60, age group dominates the market

The number of people aged 60 years or older will rise from 900 million to 2 billion between 2015 & 2050, which means growth from 12% to 22% of the total global population will be affected according to World Health Organization. Older people in low& middle income countries carry a greater disease burden than those in the rich world. The greatest causes of disability are sensory impairments, back & neck pain, chronic obstructive pulmonary disease, depressive disorders, falls, diabetes, dementia & osteoarthritis. As biological ageing is associated with person age, there is tremendous rise in people affected by osteoarthritis. In some cases the osteoarthritis is also found in adults & children as it is a genetic disorder, the effect of the disease may increase along with age if inappropriate treatment is caused.

North America holds largest share in regional analysis

The aging population, change in life style, lack of awareness of the disease, increase in genetic disorders & high cost for treatment are key factors for growth of osteoarthritis in North America. According to the National Public Health Agenda for Osteoarthritis in 2020, 1 in 7 adults are affected by osteoarthritis which holds for 32 million people in North America. FDA has approved a drug named Triluron which is used for the treatment of pain in osteoarthritis of the knee in patients who have not responded to non-surgical treatments from physical therapy and simple pain medicines. As this drug is intended to relieve pain associated with osteoarthritis in the knee for up to six months after the first dose, similar treatment are carried out to overcome osteoarthritis. Increasing prevalence ratesacross regions such as Europe & Asia Pacific tend to develop research & treatment of osteoarthritis. The associations play a vital role in awareness in the region associated with it.

Key players

Key players in this market include Sanofi SA, GlaxoSmithKline plc, Pfizer Inc, Bayer AG, Zimmer Biomet, Horizon Therapeutics PLC, Johnson & Johnson, Abbott, Eli Lilly, Anika Therapeutics, Inc, Novartis AG, Ferring Pharmaceuticals, Bioventus, Lupin Limited, FidiaFarmaceuticiS.p.A, Virchow Biotech. The key strategy includes empowering healthcare decisions regarding safety & application to the professionals, managing portfolio to sustain the business & run an efficient business model.

Historical & Forecast Period

This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029.

Report Scope by Segments

Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of product categories and region.

ATTRIBUTE DETAILS

Research Period

 2019-2029

Base Year

 2020

Forecast Period

 2021-2029

Historical Year

 2019

Unit

 USD Million

Segmentation

 By Drug Class (2019-2029; US$ Mn)

  • Analgesics
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Hyaluronic Acid
  • Pipeline Analysis

 By Anatomy (2019-2029; US$ Mn)

  • Knee
  • Hip
  • Ankle
  • Shoulder
  • Hand

 By Route of Administration (2019-2029; US$ Mn)

  • Parenteral
  • Oral
  • Topical

 By Channel of Distribution (2019-2029; US$ Mn)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online

 By Mode of Purchase (2019-2029; US$ Mn)

  • Prescription Drugs
  • Over-the-counter Drugs (OTC)

 By Region (2019-2029; US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

 Global Impact of Covid-19 Segment (2020-2021; US$ Mn)

  • Pre Covid-19 situation
  • Post Covid-19 situation

Key questions answered in this report

  • What are the key market segments in current scenario and in the future by product categories?
  • What are the key market segments in current scenario and in the future by regions?
  • What is the key impact of Covid-19 over market revenues and market determinants in the Osteoarthritis Treatment Market?
  • What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
  • What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
  • How to overcome the current market challenges and leverage the opportunities in each of the market segment?
  • Who are the key players in the Osteoarthritis Treatment Market and what are their key product categories and strategies?
  • What are the key strategies – mergers/acquisitions/R&D/strategic partnerships etc that companies are deploying to enhance market revenues and growth?

TABLE 1 Global Osteoarthritis Treatment Market Revenue, by Drug type, 2019 – 2029 (USD Mn)
TABLE 2 Global Osteoarthritis Treatment Market Revenue, by Anatomy, 2019 – 2029 (USD Mn)
TABLE 3 Global Osteoarthritis Treatment Market Revenue, by Channel of Distribution, 2019 – 2029 (USD Mn)
TABLE 4 Global Osteoarthritis Treatment Market Revenue, by Mode of Purchase, 2019 – 2029 (USD Mn)
TABLE 5 Global Osteoarthritis Treatment Market Revenue, by Route of Administration, 2019 – 2029 (USD Mn)
TABLE 6 Global Osteoarthritis Treatment Market Revenue, by Geography, 2019 – 2029 (USD Mn)
TABLE 7 North America Osteoarthritis Treatment Market Revenue, by Drug type, 2019 – 2029 (USD Mn)
TABLE 8 North America Osteoarthritis Treatment Market Revenue, by Anatomy, 2019 – 2029 (USD Mn)
TABLE 9 North America Osteoarthritis Treatment Market Revenue, by Channel of Distribution, 2019 – 2029 (USD Mn)
TABLE 10 North America Osteoarthritis Treatment Market Revenue, by Mode of Purchase, 2019 – 2029 (USD Mn)
TABLE 11 North America Osteoarthritis Treatment Market Revenue, by Route of Administration, 2019 – 2029 (USD Mn)
TABLE 12 North America Osteoarthritis Treatment Market Revenue, by Country, 2019 – 2029 (USD Mn)
TABLE 13 Europe Osteoarthritis Treatment Market Revenue, by Drug type, 2019 – 2029 (USD Mn)
TABLE 14 Europe Osteoarthritis Treatment Market Revenue, by Anatomy, 2019 – 2029 (USD Mn)
TABLE 15 Europe Osteoarthritis Treatment Market Revenue, by Channel of Distribution, 2019 – 2029 (USD Mn)
TABLE 16 Europe Osteoarthritis Treatment Market Revenue, by Mode of Purchase, 2019 – 2029 (USD Mn)
TABLE 17 Europe Osteoarthritis Treatment Market Revenue, by Route of Administration, 2019 – 2029 (USD Mn)
TABLE 18 Europe Osteoarthritis Treatment Market Revenue, by Country, 2019 – 2029 (USD Mn)
TABLE 19 Asia-Pacific Osteoarthritis Treatment Market Revenue, by Drug type, 2019 – 2029 (USD Mn)
TABLE 20 Asia-Pacific Osteoarthritis Treatment Market Revenue, by Anatomy, 2019 – 2029 (USD Mn)
TABLE 21 Asia-Pacific Osteoarthritis Treatment Market Revenue, by Channel of Distribution, 2019 – 2029 (USD Mn)
TABLE 22 Asia-Pacific Osteoarthritis Treatment Market Revenue, by Mode of Purchase, 2019 – 2029 (USD Mn)
TABLE 23 Asia-Pacific Osteoarthritis Treatment Market Revenue, by Route of Administration, 2019 – 2029 (USD Mn)
TABLE 24 Asia-Pacific Osteoarthritis Treatment Market Revenue, by Country, 2019 – 2029 (USD Mn)
TABLE 25 Rest of the World Osteoarthritis Treatment Market Revenue, by Drug Type, 2019 – 2029 (USD Mn)
TABLE 26 Rest of the World Osteoarthritis Treatment Market Revenue, by Anatomy, 2019 – 2029 (USD Mn)
TABLE 27 Rest of the World Osteoarthritis Treatment Market Revenue, by Channel of Distribution, 2019 – 2029 (USD Mn)
TABLE 28 Rest of the World Osteoarthritis Treatment Market Revenue, by Mode of Purchase, 2019 – 2029 (USD Mn)
TABLE 29 Rest of the World Osteoarthritis Treatment Market Revenue, by Route of Administration, 2019 – 2029 (USD Mn)
TABLE 30 Rest of the World Osteoarthritis Treatment Market Revenue, by Region, 2019 – 2029 (USD Mn)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +